Gemcitabine and Docetaxel With or Without Bevacizumab for Soft Tissue Sarcoma
Part of Cancer clinical trials.
This trial tests a chemotherapy combination (gemcitabine and docetaxel), given with or without bevacizumab (a drug that blocks blood vessel growth), for advanced soft tissue sarcomas that have been treated before. The goal is to see if adding bevacizumab helps slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with advanced leiomyosarcoma, undifferentiated pleomorphic sarcoma (UPS), liposarcoma, or angiosarcoma
- You have received 1–2 prior chemotherapy treatments (neoadjuvant or adjuvant counts as one)
- You are between 19 and 80 years old with good overall health (ECOG performance status 0–1)
- You have at least one measurable tumor lesion that can be tracked by imaging
- Your blood counts, kidney function, and liver function are adequate for chemotherapy
- You have not received bevacizumab, gemcitabine, or docetaxel before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (liposomal irinotecan, temozolomide, and bevacizumab) for people with advanced soft tissue sarcoma that has spread or cannot be removed by surgery. The goal is to see if this combination can help when other treatments have stopped working.
This trial tests a combination of two drugs—gemcitabine (a chemotherapy drug) and nab-sirolimus (a targeted therapy)—for people with advanced soft-tissue sarcoma or leiomyosarcoma, especially those whose tumors have a specific genetic change in the TSC2 or TSC1 genes. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests whether adding the targeted drug abemaciclib to standard chemotherapy (gemcitabine) works better against certain soft tissue sarcomas. It is for people whose tumors have a normal Rb gene, which may help the drug work.
This trial tests a new immunotherapy drug (envafolimab) combined with two chemotherapy drugs (doxorubicin and ifosfamide) for people with advanced soft tissue sarcoma who have not had prior treatment. The goal is to see if this combination is safe and effective.
This trial tests a combination of paclitaxel polymer micelles with other drugs for people with advanced bone or soft tissue sarcoma that has worsened after first-line chemotherapy. The goal is to see if this new formulation can help shrink tumors or slow their growth.
This study tests a combination of chemo medicines (gemcitabine, doxorubicin, docetaxel) plus an immunotherapy drug (nivolumab) for advanced sarcoma that can’t be removed with surgery. It may help shrink tumors and slow disease growth in people whose cancer has already been treated and is measurable on scans.
Hear when a new Neoplasms of Connective and Soft Tissue With an Unspecified Anatomical Site trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.